Press Releases

Read Regulatory and non-regulatory press releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Company Announcement Oncology Venture Publishes Q1 2020 Report for the Period January – March 2020

Non-Regulatory

Oncology Venture A/S Invites Investors for Q1 2020 Report Conference Call

Regulatory

Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions

Regulatory

Correction: Press release Oncology Venture issues 1,952,475 new shares in connection with debt conversions

Regulatory

Press release Oncology Venture secures a US $5 million (50 million SEK) equity investment from a new US based investor

Regulatory

Minutes from Annual General Meeting 2020

Regulatory

Press release Oncology Venture to test activity of its PARP inhibitor, 2X-121, as a potential therapy for Coronavirus

Regulatory

Press Release Oncology Venture is issuing 925,925 shares under its convertible note agreement with Negma Group LTD and Park Partners GB

Regulatory

Notice to convene Annual General Meeting 2020

Regulatory

Press Release Oncology Venture draws down the first tranche under its Convertible note agreement with Negma Group LTD and Park Partners GB

Regulatory

Press release Oncology Venture establishes a convertible note program of 100 million SEK

Regulatory

Press Release Oncology Venture publishes the Annual Report for 2019

Non-Regulatory

Investor News Oncology Venture A/S to Provide Investor Updates at Upcoming Events in Q2 2020

Regulatory

Press release Oncology Venture receives feedback from U.S. FDA on potential approval pathway for Dovitinib.

Regulatory

Press release Oncology Venture to present on its DRP® technology at upcoming Google Cloud NEXT Conference.

Regulatory

Press release Oncology Venture & Alpha Blue Ocean mutually terminates agreement with EHGO as part of final financing

Regulatory

Press release Oncology Venture – First day of trading in TO2 warrants

Regulatory

Press release Oncology Venture to present a poster at upcoming PARP & DDR Inhibitor Summit on clinical development of 2X-121

Non-Regulatory

Press release Oncology Venture issues 287,500 new shares in connection with a debt conversion

Non-Regulatory

Press release Oncology Venture – Registration of current rights issue